A major private hospital group warns of a crisis for advanced cancer patients under the Central Government Health Scheme. A reimbursement c...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Merck is acquiring Terns Pharma for $6.7 billion to strengthen its cancer drug pipeline, aiming to reduce reliance on its blockbuster Keytr...

Merck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-gr...

Moderna and Merck said on Tuesday their ⁠experimental personalized vaccine continued to cut the risk of death or recurrence of the most dea...

Biocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The com...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...

Dr. Reddy’s Laboratories has partnered with global biotech firm Alvotech to co-develop and commercialize a biosimilar of Keytruda (pembroli...

Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial c...

Dr. Reddy’s shares rose over 4% after announcing a global biosimilar partnership with Alvotech for Keytruda. Q4FY25 profit rose 22% YoY to ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on expe...

Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This breakthrough si...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...

The deal adds promising drug candidates to Merck's oncology portfolio, as its bestselling cancer therapy Keytruda will see its patent expir...

Data revealed that using Merck's immunotherapy drug in combination with high-risk patients decreased their risk of dying.

DCGI gave MSD permission to market Keytruda in June 2016, according to minutes of the regulator’s Subject Expert Committee on oncology and ...

The accelerated regulatory clearances cut the time lines for introductions of the two big brands which may be expected to be introduced by ...